Aptar Pharma expands APF preservative-free pump production in Argentina

Key highlights
  • Aptar Pharma has transferred and commissioned its APF production line at the Berazategui manufacturing facility in Argentina.
  • The Berazategui site dedicates 2,500 m2 to drug delivery system manufacturing and supplies customers across 15 Latin American countries.
  • The APF pump is a multidose nasal spray system for preservative‑free formulations that supports microbiological integrity through mechanical means.
  • The line transfer is part of Aptar Pharma’s global expansion and local‑for‑local strategy alongside investments in Congers (US), Suzhou (China) and Mumbai (India).
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Aptar Pharma APF Production Line Expansion Berazategui · Argentina
Operational / Completed
2026-09-11
2026-09-11
2026-09-11

Transfer and commissioning

Aptar Pharma completed the transfer and commissioning of its Aptar Pharma Preservative Free (APF) production line at the company’s manufacturing facility in Berazategui, Argentina.

Site and capacity

The Berazategui facility, south of Buenos Aires, serves as Aptar Pharma’s industrial hub in Latin America, supplying customers across 15 countries and dedicating 2,500 m2 to the manufacturing of drug delivery systems for consumer healthcare and prescription pharmaceutical markets.

APF technology

The APF pump is a multidose spray dispensing system for preservative‑free nasal formulations, designed to support microbiological integrity by mechanical means and meet rising demand for preservative‑free solutions.

Strategic context and impact

The local transfer aims to strengthen a local‑for‑local manufacturing approach, improve supply agility, reduce lead times and enhance product availability for Latin American customers. The move forms part of Aptar Pharma’s broader global expansion program, which includes capacity investments in Congers (New York), Suzhou (China) and Mumbai (India).

Source: Aptar

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

14 September 2026
Aptar Pharma and Massachusetts General Hospital build predictive nose-to-brain delivery platform

Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.

12 August 2026
Noble (Aptar Pharma) secures US patent for AI sound detection in drug-delivery and diagnostic devices

AI analyzes device-generated sounds to verify correct operation and provide objective feedback for training, usability studies and adherence in home self-administration.

28 May 2026
Aptar Pharma files patents and reports preclinical proof‑of‑concept for intranasal and pulmonary GLP‑1 delivery

Published three international patent applications for nasal/pulmonary GLP‑1 formulations (spray‑dried/powder). Preclinical semaglutide PK shows up to 10× Cmax vs oral; ongoing biologics delivery work.

19 March 2026
Aptar’s Unidose Nasal Powder System Used in ENA Respiratory Phase II INNA‑051 Study

Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.

17 March 2026
Aptar appoints Gael Touya CEO effective Sept 1, 2026; Stephan Tanda to retire end-2026

Gael Touya, a 30-year veteran, led the Pharma unit’s transformation (~82% sales growth) and has global commercial and operational experience. Tanda raised margins, EPS and sustainability.